← Back to guidelines
Dermatology185 papers

Chronic cyclosporin A nephrotoxicity

Last edited: 4/10/2026

Overview

Cyclosporine A (Cyc-A) is an immunosuppressive agent initially used for solid organ transplant recipients and graft-versus-host disease 1. While systemic administration carries risks, topical formulations are being explored for mucocutaneous disorders 1.

Diagnosis

Management

  • Topical Cyc-A is an effective treatment for oral lichen planus, psoriasis, burning mouth syndrome, pyoderma gangrenosum, and Zoon's balanitis 1.
  • Adverse effects of Cyc-A mouthwash include dysphagia, burning sensation, lip swelling, and gastrointestinal upset 1.
  • Adverse effects of Cyc-A lipogel include mild erythema, dryness, and skin fissuring 1.
  • Special Populations

    Key Recommendations

  • Topical Cyc-A is a viable alternative to traditional treatment regimens for immune-mediated mucocutaneous conditions 1. (Evidence: Moderate)
  • Topical Cyc-A mouthwash may cause dysphagia, burning sensation, lip swelling, and gastrointestinal upset 1. (Evidence: Moderate)
  • Topical Cyc-A lipogel may cause mild erythema, dryness, and skin fissuring 1. (Evidence: Moderate)
  • References

    1 Sadeghi S, Kalantari Y, Seirafianpour F, Goodarzi A. A systematic review of the efficacy and safety of topical cyclosporine in dermatology. Dermatologic therapy 2022. link

    Original source

    1. [1]
      A systematic review of the efficacy and safety of topical cyclosporine in dermatology.Sadeghi S, Kalantari Y, Seirafianpour F, Goodarzi A Dermatologic therapy (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG